340B Transparency: CMS Proposes Claims Repository For Medicare Part D Drugs

 
• By Cathy Kelly
  
Pharma believes more 340B transparency will solve discount duplication, as well as suspected diversion in the program. (Shutterstock)

More from Pricing Debate

More from Market Access